Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

2014) â€¢ ticagrelor (TA236, 2011). For a short explanation of why the committee made the 2020 recommendation and how it might affect practice, see the rationale and impact section on dual antiplatelet therapy for people with acute STEMI having primary PCI. Full details of the evidence and the committee's discussion are in evidence review A: antiplatelet therapy. Antithrombin therapy during primary PCI 1.1.12 Offer unfractionated heparin with bailout glycoprotein IIb/IIIa inhibitor in combination with dual antiplatelet therapy to people with acute STEMI undergoing primary PCI with radial access. [2020] 1.1.13 Consider bivalirudin with bailout glycoprotein IIb/IIIa inhibitor in combination with dual antiplatelet therapy for people with acute STEMI undergoing primary PCI when femoral access is needed. Acute coronary syndromes (NG185) In November 2020, use of bivalirudin with prasugrel and aspirin was off label. See NICE's information on prescribing medicines. [2020] For a short explanation of why the committee made the 2020 recommendations and how they might affect practice, see the rationale and impact section on antithrombin therapy during primary PCI. Full details of the evidence and the committee's discussion are in evidence review D: antithrombin therapy in adults with STEMI intended for primary PCI. Thrombus extraction during primary PCI 1.1.14
